Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has shared an announcement.
Clover Biopharmaceuticals Ltd. has announced the grant of 6,204,500 restricted stock units (RSUs) to its CEO and executive director, Joshua G. Liang, under its RSU scheme. These RSUs, linked to the company’s performance targets, are designed to align management incentives with shareholder interests over a ten-year period. The vesting of the RSUs is contingent upon achieving specific performance indicators such as R&D progress and financial conditions, with a clawback mechanism in place to protect against misconduct or failure to meet eligibility requirements.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. It primarily works on creating innovative vaccines and treatments, aiming to address significant global health challenges.
YTD Price Performance: -4.98%
Average Trading Volume: 1,010,014
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$297M
Learn more about 2197 stock on TipRanks’ Stock Analysis page.